RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $22 to $24.
RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $22 to $24.